{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:03:47Z","timestamp":1789643027196,"version":"4.0.0"},"reference-count":111,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-25-00690"],"award-info":[{"award-number":["25-25-00690"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["25-25-00690"],"award-info":[{"award-number":["25-25-00690"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Melanoma antigen recognized by T cells 1 (MART-1) is a tumor-associated antigen overexpressed in melanoma cells that serves as a target for different immunotherapeutic strategies. These approaches differ substantially in their efficacy and safety and are associated with various immunologic challenges, including the incidence of autoimmunity. Although multiple clinical trials evaluated anti-MART-1 immunotherapies, the available evidence is highly heterogeneous and requires systematic evaluation. The present study aimed to systematically summarize and descriptively compare the reported efficacy and safety of different MART-1-targeted immunotherapeutic strategies. Methods: Clinical trial registries and bibliographic databases were systematically searched to identify clinical trials investigating anti-MART-1 immunotherapies. Data on the objective response rate (ORR), median relapse-free survival (RFS), overall survival (OS), progression-free survival (PFS), time to progression (TTP), and adverse effects were extracted and structured. Potential immunologic challenges underlying the observed outcomes were also discussed. Results: Fifty-four clinical trials comprising 1292 treated patients were included, of whom 517 entered their trial with measurable disease and were evaluable for an objective response by RECIST. Higher objective response rates were reported in the autologous cell transfer and TCR-T trials than in the peptide- and DNA-based vaccine trials, whereas the vaccine trials reported fewer immune-related adverse events. These are uncontrolled cross-trial observations. The cell-based regimens were administered after non-myeloablative lymphodepletion and usually with high-dose IL-2, whereas the vaccination protocols were not, so the differences between modalities cannot be attributed to MART-1 targeting alone. No meta-analysis and no formal comparative efficacy analysis were performed. Conclusions: Based on the available data, MART-1-targeted immunotherapeutic strategies showed distinct efficacy and safety profiles. Higher objective response rates were reported in some adoptive cell therapy trials, together with a higher frequency of immune-related adverse events; these are uncontrolled cross-trial observations, and the contribution of concomitant lymphodepletion and IL-2 cannot be separated from that of MART-1 targeting. Peptide- and DNA-based vaccine approaches were associated with fewer immune-related adverse events and may warrant further evaluation as components of combined regimens.<\/jats:p>","DOI":"10.3390\/cancers18183016","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:59:03Z","timestamp":1789639143000},"page":"3016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Immunotherapeutic Strategies for the Treatment of MART-1-Expressing Melanoma: Systematic Review of Clinical Trials"],"prefix":"10.3390","volume":"18","author":[{"given":"Alina","family":"Alshevskaya","sequence":"first","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Tsarikova","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Golikova","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Timashev","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-7768","authenticated-orcid":false,"given":"Sergey","family":"Sennikov","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia"},{"name":"Federal State Budgetary Scientific Institution \u201cResearch Institute of Fundamental and Clinical Immunology\u201d, Novosibirsk 630099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e431608","DOI":"10.1200\/EDBK_431608","article-title":"Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies","volume":"44","author":"Haanen","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lopatnikova, J.A., and Sennikov, S.V. (2025). Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: Mechanisms of action, adverse effects, and future perspectives. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1679092"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., and Alos, L. (2021). Molecular Markers and Targets in Melanoma. Cells, 10.","DOI":"10.3390\/cells10092320"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","article-title":"Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis","volume":"28","author":"Yarza","year":"2023","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Verdon, D.J., and Jenkins, M.R. (2021). Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13164245"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hamieh, M., Chatillon, J.F., Dupel, E., Bayeux, F., Fauquembergue, E., Maby, P., Drouet, A., Duval-Modeste, A.B., Adriouch, S., and Boyer, O. (2021). Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes with Stem Cell-Like Memory Features for Melanoma Immunotherapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.674276"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bao, M., Gempeler, M., and Campiche, R. (2025). Melanosome Transport and Processing in Skin Pigmentation: Mechanisms and Targets for Pigmentation Modulation. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202508.0189.v1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Li, C., Kuai, L., Cui, R., and Miao, X. (2022). Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules, 12.","DOI":"10.3390\/biom12121874"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Arrieta-Bola\u00f1os, E., Hern\u00e1ndez-Zaragoza, D.I., and Barquera, R. (2023). An HLA map of the world: A comparison of HLA frequencies in 200 worldwide populations reveals diverse patterns for class I and class II. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.866407"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1038\/s41467-022-33720-z","article-title":"Evolution and modulation of antigen-specific T cell responses in melanoma patients","volume":"13","author":"Huuhtanen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/imcb.12231","article-title":"In vitro-generated MART-1-specific CD8 T cells display a broader T-cell receptor repertoire than ex vivo na\u00efve and tumor-infiltrating lymphocytes","volume":"97","author":"Benveniste","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/eji.201444499","article-title":"Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells","volume":"44","author":"Pinto","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/14653240902923146","article-title":"Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709)","volume":"11","author":"Duval","year":"2009","journal-title":"Cytotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Biri-Kov\u00e1cs, B., B\u00e1n\u00f3czi, Z., Tummalapally, A., and Szab\u00f3, I. (2023). Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020452"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jmb.2007.07.025","article-title":"Structures of MART-1(26\/27-35) Peptide\/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition","volume":"372","author":"Borbulevych","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Galloway, S.A.E., Dolton, G., Attaf, M., Wall, A., Fuller, A., Rius, C., Bianchi, V., Theaker, S., Lloyd, A., and Caillaud, M.E. (2019). Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00319"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/eji.201948085","article-title":"TCR-induced alteration of primary MHC peptide anchor residue","volume":"49","author":"Madura","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20210058","DOI":"10.1002\/EXP.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Exploration"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2635774","DOI":"10.1080\/07853890.2026.2635774","article-title":"Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation","volume":"58","author":"Liu","year":"2026","journal-title":"Ann. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.iotech.2022.100089","article-title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: A phase I\/IIa clinical trial","volume":"15","author":"Rohaan","year":"2022","journal-title":"Immunooncol. Technol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archderm.138.6.799","article-title":"Hypopigmentation associated with an adenovirus-mediated gp100\/MART-1-transduced dendritic cell vaccine for metastatic melanoma","volume":"138","author":"Tsao","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CMR.0000000000000556","article-title":"A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1","volume":"29","author":"Block","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/CJI.0b013e3181f1d614","article-title":"Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients","volume":"33","author":"Speiser","year":"2010","journal-title":"J. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0b013e31825481fe","article-title":"Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma","volume":"35","author":"Tarhini","year":"2012","journal-title":"J. Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/ijc.10165","article-title":"Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A\/MART-1","volume":"98","author":"Necker","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C","article-title":"Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo","volume":"67","author":"Ringhoffer","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/mt.2009.275","article-title":"Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma","volume":"18","author":"Adamina","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jnci\/90.24.1894","article-title":"Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens","volume":"90","author":"Rosenberg","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/jid.2009.144","article-title":"Treatment of metastatic melanoma with autologous melan-a\/mart-1-specific cytotoxic t lymphocyte clones","volume":"129","author":"Khammari","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.4049\/jimmunol.175.7.4797","article-title":"Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells","volume":"175","author":"Vignard","year":"2005","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.170.4.2161","article-title":"Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients","volume":"170","author":"Meidenbauer","year":"2003","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e002449","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0194599812448356","article-title":"Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma","volume":"147","author":"Seaman","year":"2012","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/mt.2015.60","article-title":"Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced with a MART-1-specific T-cell Receptor","volume":"23","author":"Hulshoff","year":"2015","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-05-1485","article-title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma","volume":"12","author":"Duval","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00002371-200007000-00013","article-title":"Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100","volume":"23","author":"Panelli","year":"2000","journal-title":"J. Immunother."},{"key":"ref_44","first-page":"998","article-title":"Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma","volume":"9","author":"Butterfield","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00002371-200409000-00004","article-title":"Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy","volume":"27","author":"Ribas","year":"2004","journal-title":"J. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01.cji.0000211309.90621.8b","article-title":"Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity","volume":"29","author":"Palucka","year":"2006","journal-title":"J. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1172\/JCI67544","article-title":"Melanoma immunotherapy using mature DCs expressing the constitutive proteasome","volume":"123","author":"Dannull","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000537896","article-title":"Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial","volume":"47","author":"Rohaan","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.cji.0000162779.88687.4c","article-title":"Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse","volume":"28","author":"Triozzi","year":"2005","journal-title":"J. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0b013e3181611420","article-title":"Phase 1 trial of intranodal injection of a melan-A\/MART-1 DNA plasmid vaccine in patients with stage IV melanoma","volume":"31","author":"Weber","year":"2008","journal-title":"J. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00262-002-0315-1","article-title":"Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma","volume":"51","author":"Nguyen","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00262-002-0313-3","article-title":"Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients","volume":"51","author":"Pandolfino","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00262-006-0204-0","article-title":"Infusion of Melan-A\/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients","volume":"56","author":"Benlalam","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/ijc.21679","article-title":"Induction of strong and persistent MelanA\/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients","volume":"118","author":"Becker","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1365-3083.2003.01324.x","article-title":"Longitudinal Analysis of MART-1\/HLA-A2-Reactive T Cells over the Course of Melanoma Progression","volume":"58","author":"Terheyden","year":"2003","journal-title":"Scand. J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.1536","article-title":"Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression","volume":"94","author":"Andersen","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CJI.0b013e31816a8910","article-title":"Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma","volume":"31","author":"Butterfield","year":"2008","journal-title":"J. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1097\/MAO.0000000000002332","article-title":"Sensorineural Hearing Loss after Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology","volume":"40","author":"Duinkerken","year":"2019","journal-title":"Otol. Neurotol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<972::AID-IJC9>3.0.CO;2-M","article-title":"Stimulation of CD8+ T cell responses to MAGE-3 and Melan A\/MART-1 by immunization to a polyvalent melanoma vaccine","volume":"72","author":"Reynolds","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e1216290","DOI":"10.1080\/2162402X.2016.1216290","article-title":"Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope","volume":"5","author":"Baumgaertner","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients\u2014Report of a Phase I\/IIa Clinical Trial","volume":"22","author":"Legat","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_63","first-page":"669","article-title":"Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A\/melanoma antigen recognized by T cells-1","volume":"9","author":"Ayyoub","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","article-title":"Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gplOO peptides plus IFN-\u03b1 results in the activation of specific CD8+ T cells and monocyte\/dendritic cell precursors","volume":"66","author":"Pilla","year":"2006","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/CJI.0b013e3181b56ad9","article-title":"Vaccination of melanoma patients with Melan-A\/Mart-1 peptide and klebsiella outer membrane protein P40 as an adjuvant","volume":"32","author":"Avril","year":"2009","journal-title":"J. Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Urbani, F., Ferraresi, V., Capone, I., Macchia, I., Palermo, B., Nuzzo, C., Torsello, A., Pezzotti, P., Giannarelli, D., and Pozzi, A.F. (2020). Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00202"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.23886","article-title":"Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients","volume":"124","author":"Capone","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_68","first-page":"2756","article-title":"Phase I trial of a MART-1 peptide vaccine with incomplete Freund\u2019s adjuvant for resected high-risk melanoma","volume":"5","author":"Wang","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_69","first-page":"37","article-title":"Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1\/Melan A","volume":"3","author":"Cormier","year":"1997","journal-title":"Cancer J. Sci. Am."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/eji.201142361","article-title":"Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients","volume":"42","author":"Goldinger","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: Results of a Phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1078-0432.CCR-10-3272","article-title":"Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: Results of a phase 1 clinical trial","volume":"17","author":"Ribas","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/imm.12675","article-title":"Antigen processing and immune regulation in the response to tumours","volume":"150","author":"Reeves","year":"2017","journal-title":"Immunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2321600121","DOI":"10.1073\/pnas.2321600121","article-title":"Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation","volume":"121","author":"Brunnberg","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e001111","DOI":"10.1136\/jitc-2020-001111","article-title":"Antigen processing and presentation in cancer immunotherapy","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e99266","DOI":"10.15252\/embj.201899266","article-title":"Proteasomal degradation within endocytic organelles mediates antigen cross-presentation","volume":"38","author":"Sengupta","year":"2019","journal-title":"EMBO J."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Buonaguro, L., and Tagliamonte, M. (2023). Peptide-based vaccine for cancer therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1210044"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41401-020-0415-5","article-title":"Ex vivo pulsed dendritic cell vaccination against cancer","volume":"41","author":"Gu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: Developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Morisaki, T., Morisaki, T., Kubo, M., Morisaki, S., Nakamura, Y., and Onishi, H. (2022). Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14102438"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13025","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: Current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Grenier, J.M., Yeung, S.T., Qiu, Z., Jellison, E.R., and Khanna, K.M. (2018). Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01993"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Abakushina, E.V., Popova, L.I., Zamyatnin, A.A., Werner, J., Mikhailovsky, N.V., and Bazhin, A.V. (2021). The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy. Vaccines, 9.","DOI":"10.3390\/vaccines9111363"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/atm.2017.06.13","article-title":"Dendritic cell therapy in melanoma","volume":"5","author":"Freire","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.cgt.7700804","article-title":"Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes","volume":"12","author":"Trakatelli","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00262-016-1820-y","article-title":"Tumor-derived factors modulating dendritic cell function","volume":"65","author":"Zong","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Xie, Y.J., Liu, W.Q., Li, D., Hou, J.C., Coghi, P.S., and Fan, X.X. (2023). Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor. Vaccines, 11.","DOI":"10.3390\/vaccines11020394"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1158\/1078-0432.CCR-11-0230","article-title":"T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: Implications for immunotherapy","volume":"17","author":"Tjin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kazemi, M.H., Sadri, M., Najafi, A., Rahimi, A., Baghernejadan, Z., Khorramdelazad, H., and Falak, R. (2022). Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1018962"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1200\/JCO.2025.43.16_suppl.9516","article-title":"Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM)","volume":"43","author":"Karapetyan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/1078-0432.CCR-04-0260","article-title":"On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients","volume":"10","author":"Bins","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/PPO.0000000000000157","article-title":"Toxicities Associated With Adoptive T-Cell Transfer for Cancer","volume":"21","author":"Yang","year":"2015","journal-title":"Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., and Chen, M. (2022). Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14174160"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: Strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2015.01.003","article-title":"TCR affinity for p\/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity","volume":"33","author":"Stone","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.1101268","article-title":"TCRs used in cancer gene therapy cross-react with MART-1\/Melan-A tumor antigens via distinct mechanisms","volume":"187","author":"Borbulevych","year":"2011","journal-title":"J. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molimm.2022.12.010","article-title":"ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes","volume":"154","author":"Schmidt","year":"2023","journal-title":"Mol. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e012029","DOI":"10.1136\/jitc-2025-012029","article-title":"Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"18766","DOI":"10.1074\/jbc.M113.464560","article-title":"T-cell receptor specificity maintained by altered thermodynamics","volume":"288","author":"Madura","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1182\/blood-2007-02-075010","article-title":"Selecting highly affine and well-expressed TCRs for gene therapy of melanoma","volume":"110","author":"Jorritsma","year":"2007","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/hgtb.2014.004","article-title":"Manufacture of gene-modified human T-cells with a memory stem\/central memory phenotype","volume":"25","author":"Nuijen","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1016\/j.vaccine.2007.08.037","article-title":"The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity","volume":"25","author":"Park","year":"2007","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.2010.04226.x","article-title":"Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell\/regulatory T cells in tumour","volume":"162","author":"Song","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1158\/0008-5472.CAN-04-1621","article-title":"Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo","volume":"64","author":"Lou","year":"2004","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CMR.0000000000000436","article-title":"Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma","volume":"28","author":"Foley","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coi.2016.01.004","article-title":"Adoptive cell therapy: A highly successful individualized therapy for melanoma with great potential for other malignancies","volume":"39","author":"Verdegaal","year":"2016","journal-title":"Curr. Opin. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:19:44Z","timestamp":1789640384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":111,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18183016"],"URL":"https:\/\/doi.org\/10.3390\/cancers18183016","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}